-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Vepdegestrant in Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Vepdegestrant in Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Vepdegestrant in Human...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – OMT-28 in Cardiomyopathy
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - OMT-28 in Cardiomyopathy report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.OMT-28 in CardiomyopathyDrug Details:OMT-28 is under development for the treatment of wet age related macular...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – KITE-222 in Relapsed Acute Myeloid Leukemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - KITE-222 in Relapsed Acute Myeloid Leukemia report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. KITE-222 in Relapsed Acute Myeloid Leukemia Drug Details: KITE-222...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – BXQ-350 in Ovarian Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - BXQ-350 in Ovarian Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.BXQ-350 in Ovarian Cancer Drug Details:BXQ-350 is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Larotrectinib Sulfate in Thyroid Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Larotrectinib Sulfate in Thyroid Cancer Drug Details: Larotrectinib Sulfate (Vitrakvi) is a anti-neoplastic agent. It...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – AIV-001
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry AIV-001 Drug Details AIV-001 is under development for the treatment of scar, low-risk basal...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – AIV-007
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry AIV-007 Drug Details AIV-007 is under development for the treatment of neovascular age-related macular...
-
Product Insights
Benign Prostatic Hyperplasia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
The symptoms of Benign Prostatic Hyperplasia (BPH) include decreased strength of the urine stream, dribbling after urination, pain during urination, waking at night to urinate, and difficulty starting a urine stream. The Benign Prostatic Hyperplasia pipeline drugs market research report provides comprehensive information on the therapeutics under development for Benign Prostatic Hyperplasia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action...